1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217: A Breakthrough in Alzheimer’s Research

11 Oct 2025
Admin
News Article

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217: A Breakthrough in Alzheimer’s Research

Alamar Biosciences, a precision proteomics company, has unveiled the NULISAqpcr™ BD-pTau217 assay—a first-of-its-kind blood-based test for measuring brain-derived phosphorylated tau 217 (pTau217), a critical biomarker in Alzheimer’s disease and other tauopathies.

Built on Alamar’s patented NULISA™ platform, this single-plex assay delivers unprecedented sensitivity and specificity from non-invasive samples like plasma, serum, or dried blood spots—no lumbar puncture or PET scan required.

“By removing noise from peripheral sources of tau, scientists can detect fundamental changes in the brain earlier and more accurately.”

Dr. Yuling Luo, Founder & CEO of Alamar Biosciences.

Why This Matters

Single-plex specificity: The only brain-derived single-plex solution available, reducing indeterminate results.
High-throughput capability: Processes over 220 samples per day with the ARGO™ HT system.
Supports discovery & translational research: Available alone or as part of the NULISAseq™ CNS Disease Panel 120.

“Early results suggest the single-plex format performs at least as well as established plasma pTau217 assays, but with a higher fold change and fewer ambiguous results,”

Jonathan Schott, MD, PhD, University College London.

Key Takeaways for Researchers

Detect Alzheimer’s disease pathology earlier in symptomatic and asymptomatic individuals.
Enable population studies and longitudinal clinical trials without invasive procedures.
Integrates seamlessly with genomics and high-sensitivity proteomics for next-gen biomarker insights.

Alamar Biosciences continues to collaborate with the neuroscience community to accelerate Alzheimer’s research and improve disease detection.

Note: NULISA BD-pTau217 tests are for research use only, not diagnostic procedures.

About Alamar Biosciences

Alamar is a privately held life sciences company focused on precision proteomics for early disease detection. Its NULISA™ platform combined with the ARGO™ HT system enables single-digit attomolar detection, surpassing the sensitivity of other protein detection technologies.